Kidney & Renal Health Research
A research overview of peptides targeting renal protection, kidney function support, and nephroprotective mechanisms — from GLP-1 renoprotection to antioxidant defense.
Renal Research Context
Oxidative Stress in Kidney Disease
The kidney is highly susceptible to oxidative damage due to its high metabolic rate. ROS from drug toxicity, ischemia, and metabolic disease drive nephron loss and progressive renal decline.
GLP-1 Receptors in Renal Tissue
GLP-1 receptors are expressed in the kidney. The FLOW trial demonstrated a 24% reduction in kidney disease progression with semaglutide in T2D patients, establishing GLP-1 renoprotection.
NAD+ Depletion in Acute Kidney Injury
NAD+ levels drop dramatically in acute kidney injury (AKI). PARP hyperactivation consumes NAD+, impairing mitochondrial function and tubular cell survival. NAD+ repletion is a therapeutic target.
Peptide Nephroprotection
Multiple peptides protect against drug-induced nephrotoxicity (NSAIDs, aminoglycosides, cisplatin) and metabolic nephropathy through anti-inflammatory, antioxidant, and tissue repair mechanisms.
Peptides Targeting Kidney & Renal Health
Renal Research Pathways
GLP-1 Renoprotection
GLP-1 receptors in the kidney mediate direct renoprotective effects. The FLOW trial established semaglutide as the first GLP-1 agonist with proven kidney disease outcome benefit.
Oxidative Stress & Antioxidants
Renal tubular cells are highly susceptible to oxidative damage. Glutathione, NAD+, and MOTS-c provide antioxidant protection and support mitochondrial function in kidney tissue.
Anti-Inflammatory Pathways
NF-κB-driven inflammation is a key driver of progressive kidney disease. BPC-157, KPV, and TB-500 inhibit inflammatory signalling and protect renal tubular cells.
NAD+ & DNA Repair
NAD+ depletion in AKI impairs PARP-mediated DNA repair and mitochondrial function. NAD+ repletion and sirtuin activation protect against tubular cell death and support recovery.
Key Studies in Renal Research
FLOW Trial: Semaglutide and Kidney Disease
Semaglutide reduced the risk of kidney disease progression by 24% in patients with T2D and chronic kidney disease. First GLP-1 agonist with proven renal outcome benefit.
BPC-157 Nephroprotection
BPC-157 protected against NSAID-induced and aminoglycoside-induced nephrotoxicity in rodent models via VEGFR2 activation and anti-inflammatory mechanisms.
NAD+ Supplementation and Renal Protection
NAD+ repletion protected against acute kidney injury by supporting PARP-mediated DNA repair and mitochondrial function in renal tubular cells.
Glutathione and Renal Oxidative Stress
Glutathione depletion is a key driver of cisplatin nephrotoxicity and oxidative renal damage. Glutathione repletion provides significant nephroprotection.
Explore These Compounds
Browse the full catalog of research peptides available from SwissNova Labs.
View All Products